The stock of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is a huge mover today! About 747,644 shares traded hands. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has declined 41.80% since March 11, 2016 and is downtrending. It has underperformed by 47.26% the S&P500.
The move comes after 7 months negative chart setup for the $3.07B company. It was reported on Oct, 14 by Barchart.com. We have $32.20 PT which if reached, will make NASDAQ:ALNY worth $276.30 million less.
Analysts await Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) to report earnings on November, 14. They expect $-1.20 earnings per share, down 31.87% or $0.29 from last year’s $-0.91 per share. After $-1.05 actual earnings per share reported by Alnylam Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 14.29% negative EPS growth.
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Ratings Coverage
Out of 14 analysts covering Alnylam Pharmaceuticals (NASDAQ:ALNY), 8 rate it a “Buy”, 0 “Sell”, while 6 “Hold”. This means 57% are positive. Alnylam Pharmaceuticals has been the topic of 29 analyst reports since August 7, 2015 according to StockzIntelligence Inc. The firm has “Buy” rating by Jefferies given on Friday, October 23. The stock of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has “Outperform” rating given on Tuesday, August 11 by FBR Capital. The company was maintained on Thursday, October 6 by Goldman Sachs. The stock has “Outperform” rating given by Leerink Swann on Tuesday, May 3. Needham maintained the shares of ALNY in a report on Thursday, October 6 with “Buy” rating. The company was downgraded on Saturday, August 22 by TheStreet. The firm has “Buy” rating given on Thursday, October 6 by Jefferies. The rating was initiated by Credit Suisse on Wednesday, January 20 with “Outperform”. The company was downgraded on Thursday, October 6 by JP Morgan. The stock of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) earned “Buy” rating by Chardan Capital Markets on Thursday, October 6.
According to Zacks Investment Research, “Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company is applying its therapeutic expertise in RNAi to address significant medical needs, many of which cannot effectively be addressed with small molecules or antibodies, the current major classes of drugs. Alnylam is building a pipeline of RNAi therapeutics; its lead program is in Phase I human clinical trials for the treatment of respiratory syncytial virus infection, which is the leading cause of hospitalization in infants in the U.S. The company’s leadership position in fundamental patents, technology, and know-how relating to RNAi has enabled it to form major alliances with leading companies including Merck, Medtronic, Novartis, and Biogen Idec.”
Insitutional Activity: The institutional sentiment decreased to 1.27 in Q2 2016. Its down 0.21, from 1.48 in 2016Q1. The ratio worsened, as 31 funds sold all Alnylam Pharmaceuticals, Inc. shares owned while 60 reduced positions. 23 funds bought stakes while 93 increased positions. They now own 72.84 million shares or 2.29% more from 71.20 million shares in 2016Q1.
Jacobs Levy Equity Inc reported 25,061 shares or 0.03% of all its holdings. Baker Bros Advsrs Ltd Partnership holds 0.01% of its portfolio in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) for 11,340 shares. Moreover, Franklin Resources Incorporated has 0.02% invested in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) for 592,000 shares. Winfield Assocs last reported 0% of its portfolio in the stock. Timessquare Capital Mgmt Ltd Limited Liability Company has invested 0.07% of its portfolio in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Metropolitan Life Insur Ny holds 0% of its portfolio in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) for 5,177 shares. New York State Common Retirement Fund, a New York-based fund reported 229,977 shares. Slate Path Cap L P has 4.93% invested in the company for 1.14 million shares. Glg Lc has 5,271 shares for 0.02% of their US portfolio. Credit Suisse Ag has 0.01% invested in the company for 209,295 shares. Wellington Group Llp last reported 0.17% of its portfolio in the stock. Hightower Advisors Limited Liability Corporation has 0% invested in the company for 3,825 shares. Parametric Associates Limited Liability Corp last reported 38,077 shares in the company. Swiss Commercial Bank owns 214,900 shares or 0.02% of their US portfolio. Blackrock Japan Ltd last reported 89,754 shares in the company.
Insider Transactions: Since April 19, 2016, the stock had 0 insider buys, and 2 insider sales for $3.98 million net activity. $2.03 million worth of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) shares were sold by MARAGANORE JOHN.
More important recent Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) news were published by: Foxbusiness.com which released: “Better Buy: Alnylam Pharmaceuticals, Inc. vs. Sarepta Therapeutics, Inc.” on October 10, 2016, also Fool.com published article titled: “What’s Next for Alnylam Pharmaceuticals, Inc. After Its Phase 3 Failure?”, Marketwatch.com published: “Alnylam Pharma stock plummets 45% after discontinuing drug on patient safety …” on October 06, 2016. More interesting news about Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) was released by: Fool.com and their article: “Better Buy: Ziopharm Oncology, Inc. vs. Alnylam Pharmaceuticals, Inc.” with publication date: September 24, 2016.
ALNY Company Profile
Alnylam Pharmaceuticals, Inc., incorporated on May 8, 2003, is a biopharmaceutical company. The Firm is engaged in developing therapeutics based on ribonucleic acid (RNA) interference (RNAi). The Firm is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate strategy for delivery of small interfering RNAs (siRNAs). The Company’s pipeline of investigational RNAi therapeutics focuses in three Strategic Therapeutic Areas (STArs): Genetic Medicines, with a pipeline of RNAi therapeutics for the treatment of rare diseases; Cardio-Metabolic Disease, with a pipeline of RNAi therapeutics toward genetically validated, liver-expressed disease in cardiovascular and metabolic diseases, such as dyslipidemia, hypertension, non-alcoholic steatohepatitis (NASH) and type II diabetes, and Hepatic Infectious Disease, with a pipeline of RNAi therapeutics for the treatment of hepatic infectious diseases.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.